Table S2. TRAEs leading to dose reductions or delays

Event	Mirvetuximab soravtansine (*N* = 243)	Chemotherapy (*N* = 109)
Any adverse event	83 (34.2)	46 (42.2)
Eye disorders	48 (19.8)	0
Blurred vision	35 (14.4)	0
Blood and lymphatic system disorders	18 (7.4)	26 (23.9)
Neutropenia	12 (4.9)	22 (20.2)
Nervous system disorders	9 (3.7)	11 (10.1)
Peripheral neuropathy[a]	9 (3.7)	8 (7.3)
Gastrointestinal disorders	8 (3.3)	4 (3.7)
Diarrhea	4 (1.6)	1 (0.9)
Respiratory, thoracic, and mediastinal disorders	5 (2.1)	1 (0.9)
Pulmonary embolism[b]	1 (0.4)	0
Investigations	4 (1.6)	0
Aspartate aminotransferase increased[b]	3 (1.2)	0
Musculoskeletal and connective tissue disorders	3 (1.2)	2 (1.8)
Arthralgia	2 (0.8)	0
General disorders and administration site conditions	1 (0.4)	14 (12.8)
Asthenia	1 (0.4)	8 (7.3)
Metabolism and nutrition disorders	1 (0.4)	0
Decreased appetite	1 (0.4)	0
Hepatobiliary disorders	0	1 (0.9)
Hypertransaminasemia	0	1 (0.9)
Infections and infestations	0	2 (1.8)
Nail infection	0	2 (1.8)
Skin and subcutaneous tissue disorders	0	7 (6.4)
Palmar-Plantar erythrodysesthesia syndrome	0	3 (2.8)

Data number of patients (%).

[a]Includes preferred terms of neuropathy peripheral, peripheral sensory neuropathy, and paresthesia

[b]Where multiple events occurred at the same frequency within a system organ class, the adverse event of highest grade is reported

TRAEs, treatment-related adverse events.